SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (7078)9/21/1999 1:03:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 9719
 
Hey, you forgot this part.......

>> Next! <<

- g -



To: biowa who wrote (7078)9/21/1999 2:09:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 9719
 
Synercid approved........

biz.yahoo.com

"The most common adverse drug reactions in comparative trials were inflammation at the infusion site (42.0%), and pain at the
infusion site (40.0%)."

"Synercid is active against these strains, although several cases of
emerging resistance occurred in VREF trials."


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News